NCT03745586View on ClinicalTrials.gov

Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

November 30, 2020

Study Completion Date

March 1, 2021

Conditions
Giant Cell Arteritis
Interventions
DRUG

Tocilizumab

Day 3: Tocilizumab infusion (8mg/kg body-weight) Day 10- week 52: Tocilizumab s.c. injections (162mg) in weekly intervals

DRUG

Glucocorticoids

Day0-day2: methylprednisolone 500mg i.v.

Trial Locations (1)

Unknown

University Hospital Bern, Inselspital, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT03745586 - Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab | Biotech Hunter | Biotech Hunter